Bronchopulmonary dysplasia is a common condition among premature infants that require ventilation after birth. It causes inflammation and scarring in their delicate lungs, leading to serious complications at the earliest and most critical stages of a preemie’s development.
Cincinnati-based Airway Therapeutics has raised $4.6 million in Series A financing for its new treatment, AT-100, that prevents BPD in preemies. The company has developed a protein, called recombinant human surfactant protein D, and plans to use the funding to jump-start formulation, manufacturing and animal testing of the new therapy. Airway has been granted orphan designation by both European regulators and the Food and Drug Administration.
Many thousands of preemies are at risk of developing this condition because they’re born before their bodies naturally produce surfactant, the substance that allows lungs to inflate. Using ventilators allows such early-term babies to breathe, of course, but it is very damaging to their delicate and immature lung tissue, Airway Therapeutics said. Babies that develop BPD are prone to repeated pneumonia, hospitalization and higher rates of asthma.
At ViVE 2024, Panelists Share Prior Authorization Progress and Frustration in Payer Insights Program
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
The research comes out of Cincinnati Children’s Hospital Medical Center, which is participating in this funding round along with CincyTech, Queen City Angels and other private investors.
